Publications

Search our bibliography using the filters on the right-hand side.

Displaying 201 through 250 of 341 publications.

Sussman G, Nakonechna A, Lynde C, Grattan C, Halliday A, Chiva-Razavi S, Hollis KA, Balp MM. Impact of chronic idiopathic/ spontaneous urticaria on health related quality of life: aSSURE-CSU study results from Canada and the UK. Poster presented at the 23rd World Congress of Dermatology; June 9, 2015. Vancouver, Canada.

Sussman G, Lynde C, Kanani A, Hebert J, Chiva-Razavi S, Chambenoit O, Khalil S, Hollis KA, McBride DW, Westlund RE, Tian H, Balp MM. ASSURE-CSU preliminary Canadian results: redefining our understanding of the clinical characteristics of patients with CSU/CIU refractory to H1- antihistamines. Poster presented at the 23rd World Congress of Dermatology; June 9, 2015. Vancouver, Canada.

Grattan C, Balp MM, Halliday A, Abouzakouk M, Hollis KA, McBride DW, Westlund RE, Wolin DL, Tian H, Alexopoulos ST, Nakonechna A. ASSURE-CSU preliminary UK results: assessing the impact of CSU on absence from work and work productivity. Poster presented at the 23rd World Congress of Dermatology; June 9, 2015. Vancouver, Canada.

McLeod LD, Mallya UG, Fox T, Zhao Y, Mordin MM, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the SDPA Annual Summer Dermatology Conference 2015; June 4, 2015. Las Vegas, NV. Previously presented at the 23rd European Academy of Dermatology and Venereology Congress.

Stull DE, McBride D, Houghton K, Finlay AY, Balp MM. Correlation between UAS7 categorical health states and DLQI score bands to assess burden of disease and response to treatment in chronic idiopathic/spontaneous patients (CIU/CSU). Poster presented at the 23rd World Congress of Dermatology; June 2015. Vancouver, Canada.

Stull DE, McBride D, Houghton K, Balp MM. Are changes in chronic urticaria symptoms and sleep experience correlated?: a post-hoc analysis from phase II trials of omalizumab in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU). Poster presented at the 23rd World Congress of Dermatology; June 2015. Vancouver, Canada.

Hawe E, Stull DE, McBride D, Balp MM. Improvement in quality of life (QOL) of patients with refractory chronic spontaneous/idiopathic urticaria (CSU/CIU) as assessed by the EURO-QOL (EQ-5D). Poster presented at the 23rd World Congress of Dermatology; June 2015. Vancouver, Canada.

Graham CN, Mollon P, Miles L, McBride D. A new cost-effectiveness framework for modeling psoriasis treatment. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Sussman G, Waserman S, Keith P, Chiva-Razavi S, Chambenoit O, Hollis K, McBride D, Westlund R. ASSURE-CSU Canadian results: assessing health utility in chronic spontaneous/idiopathic urticaria using the EQ-5D. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Sussman G, Lee J, Chiva-Razavi S, Chambenoit O, Hollis K, McBride D, Westlund R, Tian H, Balp MM. ASSURE-CSU Canadian results: assessing the impact of chronic spontaneous/idiopathic urticaria on work productivity and indirect costs. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Copley-Merriman C, Zelt S, Clark M, Gnanasakthy A. Benefits of patient-reported outcomes in dermatology drug development. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

DiBenedetti D, Baranowski E, Zelt S. Assessing patient and physician experiences with severe chronic hand eczema. Poster presented at the 73rd Annual Meeting of the American Academy of Dermatology; March 2015. San Francisco, CA. [abstract] J Am Acad Dermatol. 2015 May; 72(5 Supp 1):AB77.

Mordin M, Brown TM, McLeod L, DeMuro C, Gnanasakthy A. Two companies following the FDA pro guidance leads to similar but different measures: a case study in psoriasis. Poster presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.

Spelman LJ, Lebwohl M, Mordin M, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):73.

Foley P, Sherif B, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):56.

Collins A, Hawe E, Vickers A, Mallya UG, McBride D, Capkun-Niggli G, Olson M, Thorlund K. Secukinumab 300 mg demonstrates higher probability of efficacy than other biologics in psoriasis: indirect comparison. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia.

Sinclair R, McLeod L, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(S2):68.

Stull DE, McBride DW, Houghton KF, Balp MM. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): a post-hoc analysis from 2 randomized, double-blind, placebo-controlled phase 3 trials of omalizumab. Poster presented at the American Academy of Dermatology 73rd Annual Meeting; March 21, 2015. San Francisco, CA. [abstract] J Am Acad Dermatol. 72(5):AB43. doi: 10.1016/j.jaad.2015.02.183

Sussman G, Lynde CW, Chiva-Razavi S, Chambenoit O, Hollis K, Westlund RE, Balp MM. Canadian sub-analysis of the ASSURE-CSU study: demographic characteristics and health related quality of life in patients with chronic idiopathic urticaria. Poster presented at the American Academy of Dermatology Annual Meeting; March 21, 2015. San Francisco, CA.

Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp MM. Correlations between changes in urticaria activity score, dermatologic-related quality of life, and urticaria-specific quality of life: results from the Ph III trials of omalizumab in CIU/CSU patients. Poster presented at the American Academy of Dermatology 72nd Annual Meeting; March 21, 2015. Denver, CO.

Sussman G, Maurer M, Weller K, Nakonechna A, Abouzakouk M, Hollis K, McBride D, Balp MM, Berard F, Gimenez-Arnau AM, Frutos JO, Canonica GW, Knulst AC, Grattan C. Assessment of economic and humanistic burden of refractory chronic spontaneous/idiopathic urticaria: study design of the first observational study, ASSURE-CSU. Poster presented at the American Academy of Dermatology Annual Meeting; March 20, 2015.

Lebwohl M, Gottlieb AB, Elewski B, Rich P, Jazayeri S, Reich K, Nyirady J, Zhao Y, Tran MH, McLeod LD, Mordin MM, Nelson LM, Strober B. Secukinumab impact on patient-reported psoriasis experiences: analysis of the Psoriasis Symptom Diary from the ERASURE and FIXTURE trials. Poster presented at the 73rd Annual Meeting of the American Academy of Dermatology; March 20, 2015. San Francisco, CA.

Gottlieb AB, Strober B, Lebwohl M, Kaufmann R, Pariser D, Narbutas R, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Elewski B. Secukinumab in psoriasis: relationship between clinical- and patient-reported outcomes using clinical trial data from the ERASURE and FIXTURE trials. Poster presented at the 73rd Annual Meeting of the American Academy of Dermatology; March 2015. San Francisco, CA.

Elewski B, Lebwohl M, Strober B, Szepietowski JC, Blauvelt A, Schlessinger J, Nyirady J, Zhao Y, Tran MH, McLeod L, Odom D, Gottlieb AB. Secukinumab in psoriasis: early improvement in patient-reported symptom diary predicts clinical response. Poster presented at the 73rd Annual Meeting of the American Academy of Dermatology; March 2015. San Francisco, CA.

Stull DE, McBride D, Houghton K, Balp MM. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CU-Q2oL): is it informative about the response to treatment in CSU/CIU patients? Poster presented at the Maui Derm for Dermatologists; January 26, 2015. Maui, HI. Previously presented at the Fall Clinical Dermatology Conference.

Stull D, McBride D, Houghton K, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomized, double-blind, placebo-controlled Phase III trials of omalizumab. Poster presented at the Maui Derm for Dermatologists; January 26, 2015. Maui, HI. Previously presented at the Fall Clinical Dermatology Conference.

McLeod LD, Mallya U, Fox T, Zhao Y, Mordin MM, Strober B. Psoriasis skin clearance for patients who achieved PASI 90 provides greater HRQOL improvements than those achieved PASI 75-89. Poster presented at the Maui Derm for Dermatologists 2015; January 25, 2015. Maui, HI.

McLeod LD, Mallya UG, Fox T, Zhao Y, Mordin MM, Strober B. Psoriasis patients with PASI 90 response achieve greater health-related quality of life improvements than those with PASI 75-89 response. Poster presented at the 2015 Winter Clinical Dermatology Conference; January 16, 2015. Kaanapali, HI.

Stull D, McBride D, Houghton K, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomized, double-blind, placebo-controlled Phase III trials of omalizumab. Poster presented at the Winter Clinical Dermatology Conference; January 16, 2015. Kaanapali, HI. Previously presented at the Fall Clinical Dermatology Conference.

Twiss J, McKenna SP. Comparing the impact of psoriasis and atopic dermatitis on quality of life: co-calibration of the PSORIQoL and QoLIAD. Qual Life Res. 2015 Jan;24(1):105-13. doi: 10.1007/s11136-014-0630-y

Stull D, McBride D, Houghton K, Balp M-M. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CUQ2oL): is it informative about the response to treatment in csu/ciu patients? Poster presented at the 2015 Winter Clinical Dermatology Conference; January 2015. Kaanapali, HI. Previously presented at the Fall Clinical Dermatology Conference.

Kontoudis I, Harries M, Mohr P, Grange F, Ehness R, Benjamin L, Siakpere O, Barth J, Stapelkamp C, Pfersch S, McLeod LD, Kaye JA, Wolowacz SE. Economic burden of melanoma in three European countries: a retrospective observational study. Poster presented at the 2014 ISPOR 17th Annual European Congress; November 2014. Amsterdam, The Netherlands.

Elewski B, McLeod L, Zhao Y, Mallya U, Lewbhol M. Secukinumab versus placebo or etanercept on time to response on patient-reported psoriasis symptoms of pain, itching, and scaling (FIXTURE study). Poster presented at the Society of Dermatology Physicians Assistants Fall Dermatology Conference; November 2014. San Diego, CA. Previously presented at the 72nd Annual Meeting of the American Academy of Dermatology. doi: 10.1016/j.jaad.2014.01.781

Elewski B, McLeod LD, Zhao Y, Mallya U, Lebwohl M. Secukinumab versus placebo or etanercept on time to response on patient-reported psoriasis symptoms of pain, itching, and scaling (FIXTURE Study). Poster presented at the 15th Annual Las Vegas Dermatology Seminar; October 30, 2014. Las Vegas, NV. Previously presented at the 72nd Annual Meeting of the American Academy of Dermatology.

Gottlieb A, Zhao Y, Odom DM, Tran MH, Strober B. Secukinumab's time to psoriasis response on patient-reported psoriasis symptoms (ERASURE Study). Poster presented at the 15th Annual Las Vegas Dermatology Seminar; October 30, 2014. Las Vegas, NV.

Elewski B, McLeod LD, Zhao Y, Mallya U, Lebwohl M. Secukinumab versus placebo or etanercept on time to response on patient-reported psoriasis symptoms of pain, itching, and scaling (FIXTURE Study). Poster presented at the 33rd Anniversary Fall Clinical Dermatology Conference; October 16, 2014. Las Vegas, NV. Previously presented at the 72nd Annual Meeting of the American Academy of Dermatology.

Gottlieb A, Zhao Y, Odom DM, Tran MH, Strober B. Secukinumab's time to psoriasis response on patient-reported symptoms (ERASURE Study). Poster presented at the 33rd Anniversary Fall Clinical Dermatology Conference; October 16, 2014. Las Vegas, NV.

Stull D, McBride D, Houghton K, Balp M-M. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CU-Q2oL): is it informative about the response to treatment in CSU/CIU patients? Poster presented at the Fall Clinical Dermatology Conference; October 16, 2014. Las Vegas, NV.

Stull D, McBride D, Houghton K, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomized, double-blind, placebo-controlled, Phase III trials of omalizumab. Poster presented at the Fall Clinical Dermatology Conference; October 16, 2014. Las Vegas, NV.

Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp M-M. A positive correlation between changes in urticaria symptoms (UAS7) and dermatologic-related quality of life (DLQI) and urticaria-specific quality of life (CU-Q2oL): is it informative about the response to treatment in CSU/CIU patients? Poster presented at the European Academy of Dermatology and Venereology; October 11, 2014. Amsterdam, the Netherlands. Previously presented at the Fall Clinical Dermatology Conference.

McLeod LD, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 23rd European Academy of Dermatology and Venereology Congress; October 8, 2014.

Sherif BN, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 23rd European Academy of Dermatology and Venereology Congress; October 8, 2014.

Stull D, McBride D, Houghton K, Finlay A, Gnanasakthy A, Balp M-M. Correlation between changes in urticaria symptoms and sleep experience in patients with chronic spontaneous/idiopathic urticaria (CSU/CIU): results from two randomised, double-blind, placebo-controlled phase III trials of omalizumab. Poster presented at the European Academy of Dermatology and Venereology; October 8, 2014. Amsterdam, the Netherlands. Previously presented at the Fall Clinical Dermatology Conference.

Lebwohl M, Mordin MM, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 23rd European Academy of Dermatology and Venereology Congress; October 2, 2014. Amsterdam, The Netherlands.

Hawe E, Vickers AD, Mallya UG, McBride DW, Capkun-Niggli G, Olson M, Thorlund K. Secukinumab 300mg demonstrates highest probability of efficacy than other biologics in psoriasis: indirect comparison. Poster presented at the 23rd European Academy of Dermatology and Venereology Congress; October 2014. Amsterdam, the Netherlands.

Nakonechna A, Balp MM, Halliday A, Alexopoulos ST, Abouzakouk M, Hollis KA, McBride DW, Westlund RE, Grattan C, Tian H. UK sub-analysis of the ASSURE-CSU study: demographic characteristics and health related quality of life in patients with chronic spontaneous urticaria. Poster presented at the 23rd Congress of the European Academy of Dermatology and Venereology; October 2014. Amsterdam, the Netherlands.

Maurer M, Weller K, Nakonechna A, Abouzakouk M, Hollis KA, McBride DW, Georgiou P, Balp MM, Grattan C. The first international study assessing the economic and humanistic burden of refractory chronic spontaneous/idiopathic urticaria: aSSURE-CSU. Poster presented at the European Academy of Allergy and Clinical Immunology Congress; August 2014. Copenhagen, Denmark. [abstract] Allergy. 2014 Sep; 69(Suppl 99):122.

Mohr P, Harries M, Grange F, Ehness R, Benajmin L, Siakpere O, McLeod LD, Wolowacz SE, Kaye JA, Kontoudis I. Treatment patterns and disease burden of stage IIIB/IIIC melanoma in France, Germany and the UK. Poster presented at the ESMO 2014 Congress; September 28, 2014. Madrid, Spain. [abstract] Ann Oncol. 2014 Sep 1; 25(suppl 4):iv389. doi: 10.1093/annonc/mdu344.40

Eastman WJ, Malahias S, Delconte J, DiBenedetti D. Assessing attributes of topical vehicles for the treatment of acne, atopic dermatitis, and plaque psoriasis. Cutis. 2014 Jul;94(1):46-53.

Copley-Merriman C, Zelt S, Stone G, Barrows SM, Mordin MM, Hogue SL. Emerging-market payer needs: how should these countries be included in dermatology drug development plans? Poster presented at the 2014 ISPOR 19th Annual International Meeting; June 4, 2014.